Business Description
VivoSim Labs Inc
NAICS : 541714
SIC : 2836
ISIN : US68620A3023
Total Employee Number:
9Description
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.24 | |||||
Equity-to-Asset | -0.15 | |||||
Debt-to-Equity | -0.41 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -72.92 | |||||
Beneish M-Score | 29.39 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -53.6 | |||||
3-Year EBITDA Growth Rate | 39.7 | |||||
3-Year EPS without NRI Growth Rate | 39.1 | |||||
3-Year FCF Growth Rate | 38.1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 9.51 | |||||
9-Day RSI | 14.2 | |||||
14-Day RSI | 17.48 | |||||
3-1 Month Momentum % | -30.87 | |||||
6-1 Month Momentum % | -40.46 | |||||
12-1 Month Momentum % | -53.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.38 | |||||
Quick Ratio | 2.38 | |||||
Cash Ratio | 1.8 | |||||
Days Sales Outstanding | 88.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -58.6 | |||||
Shareholder Yield % | -323.82 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -8768.7 | |||||
Net Margin % | -10567.18 | |||||
EBITDA Margin % | -10392.37 | |||||
FCF Margin % | -8264.89 | |||||
OCF Margin % | -8264.89 | |||||
ROE % | -227.4 | |||||
ROA % | -136.63 | |||||
ROIC % | -389.28 | |||||
3-Year ROIIC % | -259.95 | |||||
ROC (Joel Greenblatt) % | -1462.77 | |||||
ROCE % | -186.52 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 7.48 | |||||
EV-to-EBIT | 0.23 | |||||
EV-to-EBITDA | 0.24 | |||||
EV-to-Revenue | -24.76 | |||||
EV-to-Forward-Revenue | 37.28 | |||||
EV-to-FCF | 0.3 | |||||
Price-to-GF-Value | 0.18 | |||||
Earnings Yield (Greenblatt) % | 434.78 | |||||
FCF Yield % | -812.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VIVS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VivoSim Labs Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.131 | ||
| EPS (TTM) ($) | -5.36 | ||
| Beta | 1.6734 | ||
| 3-Year Sharpe Ratio | -0.63 | ||
| 3-Year Sortino Ratio | -0.89 | ||
| Volatility % | 97.73 | ||
| 14-Day RSI | 17.48 | ||
| 14-Day ATR ($) | 0.106519 | ||
| 20-Day SMA ($) | 0.71025 | ||
| 12-1 Month Momentum % | -53.39 | ||
| 52-Week Range ($) | 0.3612 - 5.3 | ||
| Shares Outstanding (Mil) | 3.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VivoSim Labs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VivoSim Labs Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-16 09:00 | In 141 days | ||
| Second quarter earnings results for 2027 | 2026-11-06 | In 100 days | ||
| First quarter earnings results for 2027 | 2026-08-12 | In 14 days | ||
| Annual report for 2026 | 2026-07-14 | 0.81 (-9.21%) | ||
| Third quarter earnings results for 2026 | 2026-02-11 | 1.92 (+1.05%) | ||
| General meeting for 2025 | 2025-12-16 09:00 | 1.95 (-8.45%) | ||
| Second quarter earnings results for 2026 | 2025-11-06 | 2.28 (+8.57%) | ||
| First quarter earnings results for 2026 | 2025-08-12 | 1.78 (-0.56%) | ||
| Annual report for 2025 | 2025-06-05 | 1.83 (+3.39%) | ||
| 0.0833333:1 Stock Split | 2025-03-21 | 3.67 (+15.46%) |
Show
Entries
VivoSim Labs Inc Frequently Asked Questions
What is VivoSim Labs Inc(VIVS)'s stock price today?
The current price of VIVS is $0.38. The 52 week high of VIVS is $5.30 and 52 week low is $0.36.
When is next earnings date of VivoSim Labs Inc(VIVS)?
The next earnings date of VivoSim Labs Inc(VIVS) is 2026-08-12 Est..
Does VivoSim Labs Inc(VIVS) pay dividends? If so, how much?
VivoSim Labs Inc(VIVS) does not pay dividend.
Guru Commentaries on NAS:VIVS
No articles.
Press Release
Articles on VivoSim Labs Inc
Headlines
See More- 1
Jul 15, 2026
VivoSim expects FY27 revenue growth of over 500%, receives $5M milestone payment from Eli Lilly
Seeking Alpha • 7:12am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers